Ensysce Biosciences Acquires Cy Biopharma in $77 Million Expansion Deal
San Diego, Thursday, 6 August 2026.
On August 6, 2026, Ensysce Biosciences acquired Cy Biopharma, securing up to $77 million in financing to advance a novel therapy targeting an untreated $1 billion pain market.
Financing Structure and Capital Allocation
The transaction is underpinned by a robust financing arrangement designed to sustain operations through critical development phases. The deal structure provides immediate capital through private placement and cash reserves, alongside milestone-contingent funding to advance drug candidate CY200 through Phase 2 proof-of-concept trials [1]. The total potential value of the financing reaches up to $77 million, composed of an initial private placement of $21.5 million, $17.1 million in cash from Cy Biopharma, and a follow-on tranche of $38.6 million [1][2]. The aggregate potential capital availability is calculated as 77.2 million, ensuring liquidity for immediate strategic objectives [1].
Ownership Dilution and Investor Composition
Post-transaction ownership dynamics reflect a significant shift in equity distribution favoring the acquired entity’s stakeholders. Following full conversion and excluding the Milestone Closing, the equity breakdown will be approximately 74.94% for former Cy Biopharma equityholders, 7.57% for Ensysce, and 17.49% for new private placement investors [1]. This restructuring positions former Cy Biopharma owners as the majority stakeholders, while new investors led by Ally Bridge Group secure a substantial minority position [2]. The private placement was led by Ally Bridge Group, with participation from Perceptive Advisors, Dellora Investments, Ikarian Capital, and Adage Capital Partners, L.P. [1].
## Strategic Asset Analysis
Central to the acquisition is CY200, a clinical-stage neuroplastogenic therapy targeting Complex Regional Pain Syndrome (CRPS) Type 1. The asset holds U.S. FDA Orphan Drug Designation, a regulatory status intended to facilitate development of drugs for rare diseases [1]. This designation is particularly valuable given the condition has no currently approved therapy in a market valued at over $1 billion [2]. Ensysce Biosciences management identified the neuroplastogenic approach to complex pain as the most compelling opportunity evaluated, reinforcing conviction for the program based on supporting clinical data [1].
Development Timeline and Market Potential
The pro forma cash position is expected to fund CY200 through Phase 2 proof-of-concept data and into registrational development by 2028 [1]. James Morrison, Founder and Chief Executive Officer of Cy Biopharma, stated that upcoming Phase 2 topline data will demonstrate the potential of this approach for patients who today have no approved treatment option [2]. The financing was intentionally sized to support Cy Biopharma’s immediate strategic objectives while maintaining financial discipline in a pain market valued over $1 billion [1].
## Regulatory Pathway and Governance
Corporate governance protocols require stockholder approval for specific elements of the transaction under exchange rules. Ensysce is required to hold a stockholder meeting to obtain approval for the conversion of Series C Preferred Stock into common stock under Nasdaq listing rules [1]. The company intends to file a proxy statement with the U.S. Securities and Exchange Commission (SEC) to solicit stockholder approval, with specific disclosures regarding participants involved in the solicitation process [2]. The first tranche of the private placement is scheduled to close on August 7, 2026, while the second tranche remains dependent on achieving a clinical trial milestone [1].
Advisory and Legal Framework
A comprehensive suite of legal and financial advisors has been engaged to facilitate the transaction and ensure regulatory compliance. Key advisors include Troutman Pepper Locke LLP as legal counsel to Ensysce and Orrick, Herrington & Sutcliffe LLP as legal counsel to Cy Biopharma [2]. Financial advisory roles were fulfilled by Wedbush Securities Inc. for Cy Biopharma, and Tungsten Advisors and H. C. Wainwright & Co. for Ensysce, with Cantor and UBS Investment Bank acting as placement agents for the financing [1]. All forward-looking statements are based upon management’s estimates and forecasts as of the date hereof, reflecting current views and assumptions [2].